<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427478</url>
  </required_header>
  <id_info>
    <org_study_id>BIBW2992 ORL</org_study_id>
    <secondary_id>2010-023265-22</secondary_id>
    <nct_id>NCT01427478</nct_id>
  </id_info>
  <brief_title>Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <acronym>BIBW2992ORL</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Afatinib in maintenance
      therapy after post-operative radiochemotherapy (66 Gy and Cisplatin at the dose of 100mg/m2
      every 3 weeks)in squamous cell carcinoma of the head and neck.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The reference treatment for operated squamous cell carcinoma of the head and the neck is a
      radiochemotherapy with Cisplatin (in the dose of intravenous 100 mg / m2 IV) every 3 weeks).

      The Receptor of EGFR (Epidermal Growth Factor) or REGF is a membrane receptor; it's
      activation leads the cellular growth and inhibits apoptotic capacities. This receptor is
      overexpressed in numerous solid tumors, including ENT tumors. Several clinical studies showed
      that an over expression of the REGF in ENT tumors was a dominant factor of poor prognostic.

      Afatinib (BIBW2992) is a strong and irreversible inhibitor of the EGFR ( type 1 human
      epidermic growth factor receptor, also known as HER1) and of the HER2 (human epidermal growth
      factor receptor 2).

      Currently, 3 phase III clinical studies in postoperative situation and using an anti-REGF are
      in progress: 2 in concomitant situation with the radiotherapy and 1 both in concomitance and
      in adjuvant therapy with radiotherapy.

      The preliminary results of a phase II study show that Afatinib is efficient in patients with
      local or metastatic relapse of a squamous cell carcinoma of the sphere ENT after a first line
      with Cisplatin and its tolerance is correct.

      These data lead us to propose in post-operative situation, in patients with a squamous cell
      carcinoma of the head and neck, a radiochemotherapy with Cisplatin followed by a treatment of
      maintenance by Afatinib or by placebo.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival 2 years after the end of radiotherapy</measure>
    <time_frame>2 years after the end of radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>Every 28 days during the maintenance therapy,every 2 months during 1 year after maintenance therapy; and every 3 months during the following 3 years</time_frame>
    <description>Safety profile is characterized by type; frequency and seriousness of the toxicities showed by the patients and graded using CTCAE - V04</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patient, evaluated by questionnary</measure>
    <time_frame>Baseline; at the end of radiotherapy, at 1 and 2 years after the beginning of maintenance treatment</time_frame>
    <description>Quality of life will be evaluated at baseline; at the end of radiotherapy and also at 1 and 2 years after the beginning of maintenance treatment. The EORTC's questionnaire QLQ-C30 and the additional module &quot; Head and neck &quot; QLQ-H&amp;N35 will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Death</time_frame>
    <description>OS is the time from randomization to the date of death due to any cause or date of the last news.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>AFATINIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy combined with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Radiotherapy associated with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with placebo of BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AFATINIB</intervention_name>
    <description>AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months</description>
    <arm_group_label>AFATINIB</arm_group_label>
    <other_name>BIBW 2992</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of AFATINIB</intervention_name>
    <description>placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>Placebo of BIBW 2992</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Histologically-confirmed diagnosis of non metastatic squamous-cell carcinoma of oral
             cavity ; oropharynx, larynx or hypopharynx.

          -  Macroscopically complete resection of disease.

          -  High-risk histological features defined as :

        Microscopically incomplete tumour resection and/or invasion of regional lymph nodes with
        extracapsular extension (pN+R+)

          -  Indication of radio-chemotherapy (at least 60 Gy of radiotherapy and at least 2 cycles
             of chemotherapy)

          -  Start of radio-chemotherapy within 8 weeks after surgery

          -  Performance Status (PS) ECOG &lt;= 2

          -  Adequate Blood tests, renal and liver functions in the 15 days prior inclusion defined
             as :

        Hemoglobin &gt; 9 g/dL Neutrophil count &gt; 1500 x 109/L Platelets &gt; 100 x 109/L Total bilirubin
        &lt; 1,5x upper limit of normal (ULN) SGOT and SGPT &lt; 2,5 x ULN Alkaline Phosphatase &lt; 2,5
        xULN Serum creatinine &lt; 110 µmol/L or creatinine clearance &gt; 55 ml/min (estimated by
        Cockcroft Formula) Absence of proteinuria

          -  Women of childbearing age must use adequate means of contraception(oral hormon
             contraceptive, intrauterine contraceptive device, double barrier method of
             contraception).

          -  Mandatory affiliation with a healthy security insurance.

          -  Dated and signed written informed consent.

        Exclusion Criteria:

          -  Macroscopic residual tumour after resection(R2)

          -  Metastatic disease

          -  Prior treatment for Head and neck cancer with chemotherapy, radiotherapy or any cancer
             target therapy

          -  Prior or concomitant malignancies (except for basal cell skin cancer ; in situ
             cervical carcinoma or other malignancies with a complete response &gt; 5 years)

          -  History of heavy hypersensibility reaction to Cisplatin

          -  Uncontrolled pulmonary, cardiac , hepatic or renal disease.

          -  History of interstitial pneumopathy

          -  Significant cardiovascular disease :

        Congestive cardiac failure&gt; New York Heart Association (NYHA) Class II Myocardial
        infraction within 6 months prior to inclusion Unstable angina Severe cardiac arrythmia
        Uncontrolled hypertension while receiving appropriate medication (≥ 160 mm Hg systolic
        and/or ≥ 90 mm Hg diastolic) Disorder of left ventricular function with ejection fraction &lt;
        50% Severe cerebrovascular accident within 6 months prior to inclusion History of severe
        thromboembolism within 6 months prior to inclusion Cardiovascular baseline QTcB &gt;480 ms
        (Calculated with Bazett Formula) Bradycardia Electrolytic disorders

        - Hepatic affection like : hepatitis B or C chronic advanced decompensated hepatitis
        hepatitic cirrhosis or newly treated chronic hepatitis or nowadays treated with
        immunosuppressive drugs severe auto-immune hepatitis or disease

          -  HIV known history

          -  Recent digestive symptoms with diarrhea as :

        Crohn's disease malabsorption syndrome diarrhea Grade CTC ≥ 2

          -  Active drug or alcohol use or dependence

          -  Pregnant or breast-feeding women , or no use of effective birth control methods for
             women of childbearing potential, , or men who don't accept to use an effective birth
             control methods during the study

          -  Impossible follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Séverine RACADOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard; Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal POMMIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard , Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHIC Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Guillaume le Conquérant</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM La Timone Adultes</name>
      <address>
        <city>Marseille</city>
        <zip>13386 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>44229</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle Hospitalier Mutualiste- Centre Etienne Dolet</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strasbourg Oncologie Libérale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux du Léman</name>
      <address>
        <city>Thonon-les-bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur Bâtiment l'Atrium</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>71000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU TOURS (Hôpital Bretonneau)</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Radiothérapie Marie Curie</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de lorraine (ICL)</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54519 cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004 May 6;350(19):1945-52.</citation>
    <PMID>15128894</PMID>
  </reference>
  <reference>
    <citation>Seiwert, TC, clement, P. M, Del Campo, J, de Mont-Serrat, H., Thurm, H. C., Blackman, A. S., and Cohen, E. E. BIBW 2992 versus cetuximab in patients with metastatic or recurrent head and neck cancer (SCCHN) after failure of platinum-containing therapy with a cross-over period for progressing patients: Preliminary results of a randomized, open-label phase II study. Journal of Clinical Oncology 28(15 suppl). 2010.</citation>
  </reference>
  <reference>
    <citation>Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44.</citation>
    <PMID>15128893</PMID>
  </reference>
  <reference>
    <citation>Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990 May 15;265(14):7709-12. Review.</citation>
    <PMID>2186024</PMID>
  </reference>
  <reference>
    <citation>Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997 Dec;3(12 Pt 2):2703-7. Review.</citation>
    <PMID>10068277</PMID>
  </reference>
  <reference>
    <citation>Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232. Review.</citation>
    <PMID>7612182</PMID>
  </reference>
  <reference>
    <citation>Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer. J Cell Biochem Suppl. 1993;17F:188-91. Review.</citation>
    <PMID>8412192</PMID>
  </reference>
  <reference>
    <citation>Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol. 2000 Nov 1;18(21 Suppl):54S-9S. Review.</citation>
    <PMID>11060328</PMID>
  </reference>
  <reference>
    <citation>Fan Z, Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol. 1998 Jan;10(1):67-73. Review.</citation>
    <PMID>9466487</PMID>
  </reference>
  <reference>
    <citation>Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000 Feb;6(2):701-8.</citation>
    <PMID>10690556</PMID>
  </reference>
  <reference>
    <citation>Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81. 2006.</citation>
  </reference>
  <reference>
    <citation>Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006 Apr;79(1):15-20. Epub 2006 Apr 17.</citation>
    <PMID>16616387</PMID>
  </reference>
  <reference>
    <citation>Lapeyre M, Henrot P, Alfonsi M, Bardet E, Bensadoun RJ, Dolivet G, Favrel V, Gallocher O, Giraud P, Graff P, Guerif S, Lagarde P, Lartigau E, Marchesi V, Pommier P, Rives M, Tortochaux J, Toussaint B, Verrelle P, Bourhis J, Calais G; Groupe Oncologie Radiothérapie Tête et Cou. [Propositions for the selection and the delineation of peritumoral microscopic disease volumes in oral cavity and oropharyngeal cancers (lymph nodes excluded)]. Cancer Radiother. 2005 Jun;9(4):261-70. Epub 2005 Apr 25. Review. French.</citation>
    <PMID>16081023</PMID>
  </reference>
  <reference>
    <citation>Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, Chao C, Coche E, Cooper JS, Cosnard G, Eisbruch A, El-Sayed S, Emami B, Grau C, Hamoir M, Lee N, Maingon P, Muller K, Reychler H. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol. 2003 Dec;69(3):227-36.</citation>
    <PMID>14644481</PMID>
  </reference>
  <reference>
    <citation>Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT)(ICRU Report 83) ICRU Report 83, Journal of the ICRU Vol. 10 No. 1. 2011.</citation>
  </reference>
  <reference>
    <citation>Chao KS, Majhail N, Huang CJ, Simpson JR, Perez CA, Haughey B, Spector G. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol. 2001 Dec;61(3):275-80.</citation>
    <PMID>11730997</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>August 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2011</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck squamous cell carcinoma</keyword>
  <keyword>Post operative radio-chemotherapy</keyword>
  <keyword>Randomisation</keyword>
  <keyword>Maintenance treatment</keyword>
  <keyword>Afatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

